Clinical Trial Update: To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) [Phase 2]

View source ↗

Summary

Phase 2 LIMBER-213 evaluated the safety, tolerability, and efficacy of Itacitinib immediate-release tablets in adults with primary or secondary myelofibrosis wh…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Myelofibrosis
• Polycythemia Vera

Drugs mentioned

• Itacitinib (itacitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Myelofibrosis, Polycythemia Vera | Phase 2 | Status: COMPLETED | Results posted: 2024-09-19